VYNE Therapeutics Inc.
https://vynetherapeutics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From VYNE Therapeutics Inc.
Deal Watch: How Did J.P. Morgan Deal-Making Compare To Prior Years?
Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.
Six Chinese Biotechs Bag $403m In Fresh Financing Rounds
In immuno-oncology and beyond, Chinese investors are setting their sights on new targets in the biopharma arena.
Finance Watch: Four IPOs In One Week, And Legend Is Year’s Largest So Far
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.
Cara’s Korsuva Impresses Against Pruritus In Hemodialysis Patients
Cara Therapeutics and licensee Vifor Pharma have released positive topline data from the KALM-2 study in chronic kidney disease patients with moderate-to-severe pruritus undergoing hemodialysis, using a first-in-class selective kappa opioid receptor agonist which does not enter the CNS.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
-
Drug Delivery
- Topical Delivery
-
Drug Delivery
- Other Names / Subsidiaries
-
- Foamix Pharmaceuticals Ltd.
- Tigercat Pharma, Inc.
- Menlo Therapeutics, Inc.